Hair Loss treatment blogspot

Arch Dermatol Res. 1993;285(3):158

Morphological analysis of in vitro human hair growth.Tobin DJ,et al

edited for hair regrowth blog use

Anagen hair follicles, dissected free of contaminating connective tissue, were maintained for up to 12 days in a serum-free medium. Macroscopic observations revealed continued viability for 12 days, at which time some follicles involuted in a manner morphologically similar to catagen. Increased growth of maintained follicles was measured from the abrupt ending of the connective tissue sheath (CTS), as no increase in this component was observed from initiation of culture. In general follicles maintained up to 8 days exhibited little divergence from normal in vivo morphologies including the persistence of functional hair bulb melanocytes–a marker of anagen. After this time melanin granules were present in dermal papilla cells, as occurs during impending involution in vivo. Heterotypic cell contact occurred in the middle to upper follicle between outer root sheath (ORS) keratinocytes and disorganized CTS. Herniation of some ORS cells away from the follicle and the occurrence of loose desmosomal junctions between ORS keratinocytes reflected loss of normal follicular cell interactions in upper follicles maintained after 8 days. snip…

Hair loss and rabies vaccination in fogs
J Am Vet Med Assoc. 19815;188(10):117

Focal cutaneous vasculitis and hair loss at sites of rabies vaccination in dogs.

Wilcock BP, Yager JA.

A focal cutaneous lesion developed at the site of previous rabies vaccine administration in 13 dogs. Ten of the affected dogs were Poodles. The interval between vaccination and first observation of the lesion varied from 3 to 6 months. Skin lesions were hyperpigmented, alopecic (hair loss) macules, 2 to 5 cm in diameter. The consistent histologic lesion was vasculitis affecting arterioles of the deep dermis and subcutis. Other histologic lesions included epidermal, follicular, and adnexal atrophy, hyperpigmentation, chronic septal panniculitis, fat necrosis, and focal lymphocytic nodules in the deep dermis and subcutis. Rabies-specific fluorescence was seen in the walls of dermal blood vessels and in the epithelium of hair follicles in each of 3 dogs tested.

edited for hair loss blog

Alopecia Areata

J Am Acad Dermatol.1984;11:763

Alopecia areata: pathogenesis and treatment.

Mitchell AJ, Krull EA.

Although its etiology remains unknown, evidence has accumulated to support an autoimmune pathogenesis for hair loss in alopecia areata. Our review summarizes the immunologic data and also examines the role of genetics, atopy, and psychologic stress in this disorder. Until etiology is better understood, treatments for alopecia areata are likely to remain palliative. Nevertheless, newer therapies such as photochemotherapy, topical immunotherapy, and perhaps systemic immunotherapy (e.g., inosiplex) offer new hope for patients with extensive disease.

hair loss treatment blog

Topical minoxidil for hair regrowth.
J Am Acad Dermatol.1984;11.

Topical minoxidil for hair regrowth.

Vanderveen EE, et al

Minoxidil, a potent peripheral vasodilator used orally for refractory hypertension, has produced hypertrichosis. To determine the efficacy and safety of 1% or 5% topical minoxidil for the stimulation of scalp hair regrowth, we studied fifteen normotensive patients, five with androgenic alopecia and ten with alopecia areata diagnosed clinically and by biopsy, for 12 months. Three of five patients with androgenic alopecia using 5% minoxidil for 12 months noted hair regrowth, ranging from minimally observable hair to an appreciable restoration of larger, pigmented, terminal hair in one patient. Among the patients with androgenic alopecia ( pattern hai rloss) , the hair regrowth response corresponded to the serum minoxidil blood levels. None of the patients with alopecia areata receiving either 1% or 5% minoxidil noted hair regrowth despite comparable minoxidil blood levels. Improved local absorption of topical minoxidil solution may promote hair regrowth in androgenic alopecia.

Br J Dermatol. 1992 Feb;126(2):166

Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice.

Gilhar A, et al

We have previously demonstrated regrowth of hair in scalp skin grafts taken from patients with alopecia areata (AA) and alopecia universalis (AU) following engraftment on to nude mice. This present study was to determine whether serum from patients with AA and AU, has a role in the process of hair loss and the role of antibodies and complement. Forty mice were grafted with transplants obtained from seven patients. One group of the grafted mice was given patients’ serum and another group normal serum. The mice were treated topically with cyclosporin (CyA), or olive oil. Hair regrowth was noted in most grafts and intravenous injections of serum did not prevent or inhibit this process. Immunofluorescence studies before grafting showed deposition of immunoglobulins and complement in hair follicles in both normal and affected scalp skin, but a more striking deposition was noted in the affected skin. Deposition of immunoreactants after grafting was observed only after the injection of serum from the patients but not with normal serum. Thus the sera from patients with AA or AU, when injected into nude mice with hair transplants from the scalp skin of patients with these disorders, does not alter the hair growth despite deposition of immunoreactants around the hair follicles.

Int J Dermatol. 1992 31(2):103

Expression of T6 antigen on keratinocytes in alopecia areata.

Lotti T, et al

The expression of T6 antigen within hair follicles in hair loss due to alopecia areata was studied using the APAAP technique (alkaline phosphatase monoclonal anti-alkaline phosphatase method). Scalp biopsies were taken from 15 subjects with alopecia areata, nine in an active stage and 6 in a stationary stage of the disease. Six-micrometer-thick frozen sections were stained with OKT6 antiserum. OKT6 are monoclonal antibodies raised against human thymocytes; they cross-react with epidermal Langerhans cells and are a highly specific marker. Nine of the specimens displayed T6 staining on keratinocytes in the bulb matrix, and all nine were from the subjects presenting the active stage of disease. The specimens from the other six biopsies, from subjects in a stationary stage, did not show T6 staining of bulbar keratinocytes. Moreover, in four of the active-stage cases we found T6 staining also on epidermal keratinocytes.

Br J Dermatol. 1976 Mar;94 suppl 12:51-8.

The place of intralesional steroid therapy in dermatology.

Verbov J.

Intralesional steroid therapy has a definite, if small, place in dermatology and triamcinolone acetonide is the preparation in most common use. Such therapy may be used, particularly in nail disorders, keloids and hypertrophic scars, cystic acne, and to speed regrowth of hair in localized alopecia areata. Other conditions in which it has a place include cutaneous lupus erythematosus and sarcoidosis. There are some conditions where use is occasionally indicated and yet others where further trial is merited.